Neoadjuvant antibody-drug conjugates for early-stage breast cancer: A systematic review and meta-analysis.
BACKGROUND: Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth fa CONCLUSION: Neoadjuvant ADC-based strategies yield clinically meaningful pCR rates in EBC, with the greatest benefit in HER2+ disease, supporting further investigation and biomarker-guided patient selection. Full text review required for further details.
BACKGROUND: Pathologic complete response (pCR) is a key endpoint of neoadjuvant therapy in early-stage breast cancer (EBC), associated with improved survival, particularly in triple-negative and human epidermal growth fa CONCLUSION: Neoadjuvant ADC-based strategies yield clinically meaningful pCR rates in EBC, with the greatest benefit in HER2+ disease, supporting further investigation and biomarker-guided patient selection. Full text review required for further details.
What the study was
- Study design
- Meta-Analysis
- Population
- n=363
- Sample size
- 363
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Critical reviews in oncology/hematology
Why it surfaced
Scored 8/10 (Meta-Analysis; novelty=2, relevance=3, design_quality=2, population_or_unmet_need=1). HIGH priority.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.